Corporate and regulatory developments over the Christmas period
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
Source flop raises tezepelumab questions
Astrazeneca and Amgen hope the “totality of the data” will win out for their asthma project.
Uniqure’s safety scare shakes haemophilia gene therapy
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.
Gilead would rather forget filgotinib
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
Incyte’s Jakafi disappoints in severe Covid-19
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
